Join us on Tuesday 3 September 2013 to hear Andrew Laslett from CSIRO Material Science & Engineering discuss novel tools for human stem cell biology and how these can be used to harness pluripotency.
4-5pm (refreshments served following seminar)
Level 5 Seminar Room, Melbourne Brain Centre, The University of Melbourne
Dr Laslett and his laboratory have developed a FACS-based immunotranscriptional profiling system for identifying and isolating human embryonic stem cells (hESC) that express high levels of the cell surface antigens CD9 and GCTM-2 and have demonstrated that these cells represent a highly enriched population of hESC [1-3]. This work has used multiple hESC lines (MEL1, HES2 & H9) and culture conditions (serum based culture, KOSR and MEFS, mTESR1 and matrigel) and combines immunotranscriptional and membrane polysome translation state analysis. These studies identified a refined genetic signature for hESC and have since been extended using multiple human induced pluripotent stem (iPS) cell lines. The immunotranscriptional profiling also provides a detailed understanding of the earliest events in pluripotent stem cell differentiation and has enabled the identification of target genes that switch off very rapidly as differentiation commences. We are currently utilising these methodologies and information to; (i) produce and characterise novel antibodies to new cell surface markers for pluripotent cells and (ii) to demonstrate critical differences between human iPS cell lines, generated using distinct methodologies both with and without genetic modification, and hESC. Results generated utilising teratoma formation and colony forming assays demonstrate functional differences between hESC and iPS cell lines .
1. Laslett, A. L. et al. (2007). BMC Dev Biol 7: 12.
2. Kolle, G. et al. (2009) STEM CELLS 27:2446–2456
3. Hough, S. et al. (2009) PLOS One 2009 Nov 5;4(11):e7708.
4. Polanco, J.C. et al. (2013) STEM CELLS (epub ahead of print)
Andrew Laslett is Research Group Leader with CSIRO Materials Science and Engineering, where he leads a human pluripotent stem cell biology research group. Since 2007, Andrew and his laboratory have focused on elucidating the complex biology of human embryonic stem cells (hESC), examined methods for the differentiation of hESC to renal progenitor cells and more recently begun comparing hESC to reprogrammed human cells termed induced pluripotent stem (iPS) cells. His laboratory is currently focused on exploiting the basic biology of these cell types to create novel cell lines and tools that enhance human pluripotent cell research translation within CSIRO, Australia and internationally. He leads an independent research program as well as having significant national and international collaborations.